2024
Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementMagnetic Resonance Imaging in Prostate Cancer Screening
Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.Peer-Reviewed Original ResearchClinically significant PCaDetection of clinically significant PcaInternational Society of Urological PathologyClinically significant PCa detectionProstate magnetic resonance imagingMagnetic resonance imagingInsignificant PCaProstate cancerProstate cancer screeningBiopsy indicationClinically significant PCa detection rateProstate-specific antigen (PSA)-based screeningMagnetic resonance imaging pathwayOdds ratioPCa detection rateSignificant PCaPI-RADS scorePSA-based screeningResonance imagingScreening pathwayTime of magnetic resonance imagingPositive predictive valuePooled odds ratioProspective cohort studyRandomized clinical trials‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Ellis S, Loeb S, Schulman‐Green D, Leapman M. ‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer. BJUI Compass 2024, 5: 593-601. PMID: 38873351, PMCID: PMC11168777, DOI: 10.1002/bco2.351.Peer-Reviewed Original ResearchProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerActive surveillanceActive surveillance of prostate cancerGleason Grade Group 1Surveillance of prostate cancerIntermediate-risk prostate cancerMonitoring of prostate cancerMRI-ultrasound fusion biopsyGrade group 1Monitoring prostate cancerGroup 2 tumorsMagnetic resonance imaging scansFusion biopsyLongitudinal follow-upProstate biopsyFollow-upProstateSemi-structured interviews of patientsMRI useQualitative studyGroup 1Interviews of patientsPatientsReliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology
Zeevi T, Leapman M, Sprenkle P, Venkataraman R, Staib L, Onofrey J. Reliable Prostate Cancer Risk Mapping From MRI Using Targeted and Systematic Core Needle Biopsy Histopathology. IEEE Transactions On Biomedical Engineering 2024, 71: 1084-1091. PMID: 37874731, PMCID: PMC10901528, DOI: 10.1109/tbme.2023.3326799.Peer-Reviewed Original ResearchMagnetic resonance imagingIndividual patientsBiopsy locationProstate biopsy dataBiopsy histopathologyHistopathology scoresPathology scoresBiopsy dataMRI biomarkersTreatment planPatientsResonance imagingProstate regionBiomarkersTherapy treatment plansPathologyRepresentative sampleScoresImaging analysisPrevious studiesHistopathologyProstateCancerClinicians
2023
Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy
Leapman M, Thiel C, Gordon I, Nolte A, Perecman A, Loeb S, Overcash M, Sherman J. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. European Urology 2023, 83: 463-471. PMID: 36635108, DOI: 10.1016/j.eururo.2022.12.008.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingSystematic biopsyProstate biopsyProstate biopsy procedureResonance imagingBiopsy coresTransrectal Ultrasound Guided Prostate BiopsyBiopsy procedureMultiparametric magnetic resonance imagingUnnecessary prostate biopsiesBiparametric magnetic resonance imagingOutpatient urology clinicNumber of biopsiesGuided Prostate BiopsyAcademic medical centerHealth care facilitiesEvidence-based approachUrology clinicClinical managementMedical CenterTriage strategiesClinical careTransrectal ultrasoundBiopsyProstate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2018
Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer
Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerDefinitive treatmentPCa diagnosisEnd Results-Medicare databaseResonance imagingMultivariable logistic regression analysisPropensity scoreDiagnosis of PCaUse of MRIConditional logistic regression modelsLogistic regression analysisLogistic regression modelsInitial managementMultivariable analysisGreater oddsPatientsSocioeconomic statusDiagnosisHigher likelihoodRegression analysisDemographic factorsCancerMP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT
Leapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT. Journal Of Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.Peer-Reviewed Original ResearchOutcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.
Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.Peer-Reviewed Original ResearchMRI/US fusion biopsyLow-risk prostate cancerNational Comprehensive Cancer NetworkFusion biopsyActive surveillanceSystematic biopsyProstate cancerGleason upgradeMagnetic resonance imagingPSA densitySubsequent biopsyFavorable-risk prostate cancerMRI/ultrasound fusionSerial magnetic resonance imagingProportion of patientsRisk prostate cancerComprehensive Cancer NetworkLow-risk criteriaRisk of reclassificationLogistic regression modelsBiopsy upgradeMedian PSAGleason scoreHigher PSAInstitutional database
2016
MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2
Leapman M, Wang Z, Behr S, Kurhanewicz J, Zagoria R, Carroll P, Guimarães C, Westphalen A. MP79-10 PROTON MAGNETIC RESONANCE IMAGING SPECTROSCOPY IMPROVES PREDICTION OF HIGH GRADE PROSTATE CANCER WHEN INTEGRATED IN PI-RADS 2. Journal Of Urology 2016, 195: e1038. DOI: 10.1016/j.juro.2016.02.2008.Peer-Reviewed Original Research